Search - tctmd.com

Displaying 461 - 480 of 492

Sort: Relevancy | Date

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Michael O'Riordan

September 16, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

阿波罗月球宇航员死于心脏病导致专家探讨深空心血管安全问题

Michael O'Riordan

August 01, 2016

News Daily News

Las Muertes por Causas Cardiovasculares de los Astronautas del Proyecto Apolo Plantean Cuestiones de Seguridad CV en el Espacio Profundo

Michael O'Riordan

August 01, 2016

News Daily News

Apollo Lunar Astronauts Dying of Heart Disease Pose CV Safety Questions for Deep Space

Michael O'Riordan

August 01, 2016

News Daily News

药物治疗的使用不足与高龄患者不良事件增多相关

Michael O'Riordan

July 21, 2016

News Daily News

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Michael O'Riordan

July 21, 2016

News Daily News

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Michael O'Riordan

July 21, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

Advertisement

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

阿波罗月球宇航员死于心脏病导致专家探讨深空心血管安全问题

Las Muertes por Causas Cardiovasculares de los Astronautas del Proyecto Apolo Plantean Cuestiones de Seguridad CV en el Espacio Profundo

Apollo Lunar Astronauts Dying of Heart Disease Pose CV Safety Questions for Deep Space

药物治疗的使用不足与高龄患者不良事件增多相关

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content